Geron Corporation (GERN)

Geron Corp.'s stock has experienced several notable events in the past six months. In Q1 2026, Geron reported revenue exceeding expectations, but the stock declined. The company experienced a significant premarket decline following a disappointing Q4 2025 earnings report. Over the past six months, GERN shares have delivered a 53% return, with volatility. Timothy Williams was appointed as Chief Legal Officer, and Patricia Andrews and Constantine Chinoporos were added to its board. Geron filed a follow-on equity offering of up to $150 million in common stock and reported inducement stock option grants to newly hired employees.

Information regarding specific demand seasonality for Geron Corp.'s products and services is limited. In Q1 2026, RYTELO saw demand growth and an increase in prescribing accounts. There might be some fluctuations in demand throughout the year, but no clear, recurring seasonal pattern is explicitly detailed.

Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic products for oncology, specifically hematologic myeloid malignancies. The company's core business revolves around telomerase inhibition, with its primary therapeutic product being RYTELO (imetelstat), approved in the United States and the European Union for treating adult patients with low- to intermediate-1 risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. Geron's product pipeline includes several other imetelstat-based candidates in various clinical trial phases for other hematologic malignancies.

Geron Corporation is headquartered in Foster City, California, United States. RYTELO has received regulatory approvals and is commercialized in both the United States and the European Union, indicating its primary markets.

Geron Corp.'s brand reputation appears mixed, with positive developments in product approval and revenue growth, but also challenges in profitability and stock performance. Geron has a consensus "Hold" rating from analysts, with an average rating score of 2.00. The company has a GF Score™ of 51/100, indicating average performance relative to its peers. The FDA and EU approval of RYTELO has been a significant positive, while the Q4 2025 earnings miss and Q1 2026 stock decline suggest market concerns. A workforce reduction in December 2025 could be perceived in various ways.

Geron Corporation's ownership is a mix of institutional, retail, and individual investors. Key institutional shareholders include Ra Capital Management, L.P., BlackRock, Inc., and Vanguard Group Inc. Peter Kolchinsky is noted as owning the most shares of Geron Corp. among individuals.